semaglutide and resting heart rate increase Glucagon-like peptide-1 increases by a direct action on the sinus node Why GLP-1 Medications Increase Heart – Tirzepatide and Heart Rate: Clinical

In the STEP 1 trial 23 , the mean change in body weight from baseline to 68 weeks was 14.9%, compared with 2.4% with placebo

And there are receptors in our body at multiple sites

For Wegovy (higher-dose semaglutide for weight management), rates were higher, affecting approximately 29.3% of patients across the STEP clinical trials, with most cases occurring during dose escalation phases

Most users begin noticing appetite changes in the first few weeks and measurable weight loss by weeks 48

Oral Wegovy and Rybelsus must be taken in the morning on an empty stomach

However, semaglutide users may experience mild fluid shifts or blood pressure changes